Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia

Blood

Volumn 94, Issue 3, 1999, Pages 1046-1056

  Legrand, Ollivier ^a,b   Simonin, Ghislaine ^a   Beauchamp Nicoud, Anne ^a   Zittoun, Robert ^a   Marie, Jean Pierre ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CALCEIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PROBENECID;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CYTOGENETICS; FLOW CYTOMETRY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033179207     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.3.1046.415k03_1046_1056     Document Type: Article

References (61)

1. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R: MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 32A: 1034, 1996
2. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650, 1992
3. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken GK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM, Pinedo HM: Over-expression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475, 1993
4. Zhou DC, Zittoun R, Marie J-P: Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 9:1661, 1995
5. List AF, Spier CS, Grogan TM, Jonhson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS: Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464, 1996
6. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Ming-Chen I, Head DR, Appelbaum FR, Willman CL: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323, 1997
7. Leith CP, Kopecky KJ, Chen IM, Slovak M, Head DR, Weick J, Appelbaum FR, Wiilman CL: Frequency and clinical significance of expression of the multidrug resistance proteins, MDR1, MRP and LRP in acute myeloid leukemia patients less than 65 yrs old. A Southwest Oncology Group study. Blood 90:389a, 1997 (abstr, suppl 1)
8. Filipits M, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R: Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome. Clin Cancer Res 3:1419, 1997
9. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechner K, Pirker R: Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91:1508, 1998
10. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie J-P: Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91:4480, 1998
11. Bailly JD, Muller C, Jaffrézou JP, Demur C, Gassar G, Bordier C, Laurent G: Lack of correlation between expression and function of Pgp in acute myeloid leukemia cells. Leukemia 9:799, 1995
12. Legrand O, Simonin G, Zittoun R, Marie J-P: Both P-gp and MRP contribute to drug resistance in AML. Leukemia 12:1327, 1998 (letter)
13. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B: Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268:21493, 1993
14. Feller N, Broxterman HJ, Wahrer DC, Pinedo HM: ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): No inhibition by intracellular glutathione depletion. FEBS Lett 368: 385, 1995
15. Broxterman HJ, Sonneveld P, Feller N, Osenkoppele GJ, Währer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Löwenberg B, Schuurhuis GJ: Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity. Blood 87:4809, 1996
16. Barrand MA, Bagrij T, Neo SY: Multidrug resistance-associated protein: A protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Gen Pharmacol 28:639, 1997
17. Chitnis M, Hegde U, Chavan S, Juvekar A, Advani S: Expression of the multidrug transporter P-glycoprotein and in vitro chemosensitivity: Correlation with in vivo response to chemotherapy in acute myeloid leukemia. Sel Cancer Ther 7:165, 1991
18. Noogaard JM, Bukh A, Langkjer ST, Clausen N, Palshof T, Pedersen B, Hokland P: MDR1 gene expression and drug resistance of AML cells. Br J Haematol 100:534, 1998
19. Efferth T, Fabry U, Osieka R: Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 11:1180, 1997
20. Slapak CA, Mizunuma N, Kufe DW: Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 84:3113, 1994
21. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC, Sehested M: Sequential coexpression of the multidrug resistance gene MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 55:459, 1995
22. Zhou DC, Ramond S, Viguié F, Faussat AM, Zittoun R, Marie J-P: Progressive resistance to homoharringtonine in human myeloleukemia K562 cells: Relationship to sequential emergence of MRP and MDR1 gene overexpression and MDR1 gene translation. Int J Cancer 65:365, 1996
23. van der Kolk DM, de Vries EG, Koning JA, van den Berg E, Muller M, Vellenga E: Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral cells. Clin Cancer Res 4:1727, 1998
24. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick NR Sultan C: The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol 47:553, 1981
25. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gallon DAG, Gralnick NR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:620, 1985
26. Arthur DC, Berger R, Golomb HM, Swanbury GJ, Reeves BR, Alimena G, Van Den Berghe H, Bloomfield CD, De la Chapelle A, Dewald GW, Garson OM, Hagemeijer A, Kaneko Y, Mitelman F, Pierre RV, Ruutu T, Sakurai M, Lawler SD, Rowley JD: The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 40:203, 1989
27. Legrand O, Perrot J-Y, Tang RP, Simonin G, Gurbuxani S, Zittoun R, Marie J-P: Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haematopoietic cells. Br J Haematol 94:23, 1996
28. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dielt M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Kumar Svrivastava D, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R: Methods to detect P-glycoprotein-associated multidrug resistance in patient tumors: Consensus recommendations. Cancer Res 56:3010, 1996
29. Marie J-P, Huet S, Faussat A-M, Perrot J-Y, Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F, Campos-Guyotat L, Colosetti P, Cazin J-L, De Cremoux P, Delvincourt C, Demur C, Drenou B, Fenneteau O, Feuillard J, Garnier-Suillerot A, Genne P, Gorisse M-C, Gosselin P, Jouault H, Lacave R, Le Calvez G, Léglise M-C, Léonce S, Manfait M, Maynadié M, Merle-Béral H, Merlin J-L, Mousseau M, Morjani H, Picard F, Pinguet F, Poncelet P, Racadot E, Raphael M, Richard B, Rossi J-F, Schlegel N, Vielh P, Zhou DC, Robert J: French Network of the Drug Resistance Intergroup, and Drug Resistance Network of 'Assistance Publique-Hôpitaux de Paris': Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 11:1086, 1997
30. Marie J-P, Legrand O, Perrot J-Y, Chevillard S, Huet S, Robert J: Measuring multidrug resistance expression in human malignancies: Elaboration of concensus recommendations. Semin Hematol 34:63, 1997
31. Hollo Z, Homolya L, Hegedus T, Sarkadi B: Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 383:99, 1996
32. Hollo Z, Homolya L, Davis CW, Sarkadi B: Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1191:384, 1994
33. Gollapudi S, Kim CH, Tran BN, Sangha S, Gupta S: Probenecid reverses multidrug resistance in resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother Pharmacol 40:150, 1997
34. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M: Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry 17:84, 1994
35. Plumb JA, Milroy R, Kaye SB: Effect of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49:4435, 1989
36. Kaspers GJL, Veerman AJP, Pierters R, Broekema GH, Huismans DR, Kasimier KM, Loonen AH, Van Zantwijk CH, Hälen K, Van Wering ER: Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methylthiazol-tetrazolium assay. Br J Cancer 70:1047, 1994
37. Albert DS, Bachur NR, Holtzman JL: The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther 12:96, 1971
38. Farina P, Marzillo G, D'Incalci M: High-performance liquid chromatography determination of 4′-demethylepipodophyllotoxin-9 (4,6-O-ethylidene ß-D-glucopyranoside) (VP16-213) in human plasma. J Chromatogr 222:141, 1981
39. Damon LE, Plunkett W, Linker CA: Plasma and cerebrospinal fluid pharmacokinetics of 1-ß-D-arabinofuranosylcytosine and 1-ß-D arabinofuranosyluracil following the repeated intravenous administration of high and intermediate dose of 1-ß-D-arabinofuranosylcytosine. Cancer Res 51:4141, 1991
40. Kaplan EI, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1976
41. Cox DR: Regression models and life tables (with discussion). J Royal Stat Soc B 34:187, 1972
42. Slapak CA, Daniel JC, Levy SB: Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: Decreased anthracycline uptake precedes increased P-glycoprotein expression. Cancer Res 50:7895, 1990
43. Richon VM, Weich N, Leng L, Kiyokawa H, Ngo L, Rifkind RA, Marks PA: Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation. Proc Natl Acad Sci USA 88:1666, 1991
44. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB: Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 8:2163, 1994
45. Nooter K, Westerman AM, Flens MJ, Zaman GJR, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, Gratama JW, Kok T, Eggermont AMM, Bosman FT, Stoter G: Expression of the multidrug resistance associated protien (MRP) gene in human cancer. Clin Cancer Res 1:1301, 1995
46. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186, 1995
47. Ross DD, Doyle LA, Schiffer CA, Lee EJ, Grant CE, Cole SPC, Deeley RG, Yang W, Tong Y: Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia patients. Leukemia 10:48, 1996
48. Burger H, Nooter K, Zaman GJR, Sonneveld P, van Wingerden KE, Oostrum RG, Stoter G: Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8:990, 1994
49. Schuurhuis GJ, Broxterman HJ, Ossenkeppele GJ, Baak JPA, Eekman CA, Kuiper CM, Feller N, van Heijningen THM, Klumper E, Pierters R, Lankelma J, Pinedo HM: Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with -beta-d-arabinosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1:81, 1995
50. Klumper E, Ossenkoppele GJ, Pieters R, Huismans DR, Loonen AH, Rottier A, Wertra G, Veerman JP: In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukemia. Br J Haematol 3:903, 1996
51. Salmon SE: Chemosensitivity testing: Another chapter. J Natl Cancer Inst 82:32, 1990
52. Pierters R, Huismans DR, Loonen AH, Hälen K, van der Does van den Berg A, van Wering ER, Veerman AJP: Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338:399, 1990
53. Kaspers GJL, Veerman AJP, Pierters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van Der Does-Van Den Berg A: In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90:2723, 1997
54. Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C: In vitro drug testing in patients with acute leukaemia with incubation mimicking in vivo intracellular drug concentrations. Eut J Haematol 43:374, 1989
55. Vogler WR, McCarley DL, Stagg M, Bartolucci AA, Moore J, Martelo O, Omura GA: A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group Trial. Leukemia 8:1847, 1994
56. Hann IM, Stevens RF, Goldstone AH, Rees JKH, Wheatley K, Gray RG, Burnett AK on behalf of the Adult and Childhood Leukaemia Working Parties of the Medical Research Council: Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adult with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Blood 89: 2311, 1997
57. Odom LF, Gordon EM: Acute monoblastic leukaemia in infancy and early childhood: Successful treatment with an epipodophyllotoxin. Blood 64:875, 1984
58. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Kronenberg H, Ma D, Dodds A, Hermann R, Szer J, Wolf MM, Young G for the Australian Leukemia Study Group: Etoposide in acute nonlymphoblastic leukemia. Blood 75:27, 1990
59. Rowe JM, Liesveld JL: Treatment and prognostic facrtors in acute myeloid leukaemia. Baillieres Clin Haematol 9:87, 1996
60. Legrand O, Zittoun R, Marie JP: Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 13:578, 1999
61. Legrand O, Simonin G, Zittoun R, Marie JP: Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: A critical evaluation by three techniques. Leukemia 12:1367, 1998